Benefit with neoadjuvant pembrolizumab

Affiliations

Comment

Diana Romero. Nat Rev Clin Oncol. 2022 Dec.

. 2022 Dec;19(12):748.

doi: 10.1038/s41571-022-00702-5.

No abstract available

Comment on

Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Basile G, et al. Clin Cancer Res. 2022 Dec 1;28(23):5107-5114. doi: 10.1158/1078-0432.CCR-22-2158. Clin Cancer Res. 2022. PMID: 36190522 Clinical Trial.

1. Basile, G. et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-2158 (2022) - DOI - PubMed